The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Turkiye
| dc.contributor.author | Gul, Fethi | |
| dc.contributor.author | Kasapoglu, Umut Sabri | |
| dc.contributor.author | Sabaz, Mehmet Suleyman | |
| dc.contributor.author | Ay, Pinar | |
| dc.contributor.author | Oktay, Burcin Doruk | |
| dc.contributor.author | Caliskan, Gulbahar | |
| dc.contributor.author | Demir, Nalan | |
| dc.date.accessioned | 2024-02-23T14:38:04Z | |
| dc.date.available | 2024-02-23T14:38:04Z | |
| dc.date.issued | 2023 | |
| dc.department | NEÜ | en_US |
| dc.description.abstract | Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.Study Design: Multicenter prospective observational clinical study.Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged >= 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 +/- 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients. | en_US |
| dc.identifier.doi | 10.4274/balkanmedj.galenos.2023.2023-6-90 | |
| dc.identifier.endpage | 444 | en_US |
| dc.identifier.issn | 2146-3123 | |
| dc.identifier.issn | 2146-3131 | |
| dc.identifier.issue | 6 | en_US |
| dc.identifier.pmid | 37867428 | en_US |
| dc.identifier.scopus | 2-s2.0-85175039964 | en_US |
| dc.identifier.scopusquality | Q3 | en_US |
| dc.identifier.startpage | 435 | en_US |
| dc.identifier.uri | https://doi.org/10.4274/balkanmedj.galenos.2023.2023-6-90 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12452/16348 | |
| dc.identifier.volume | 40 | en_US |
| dc.identifier.wos | WOS:001094980300009 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Galenos Publ House | en_US |
| dc.relation.ispartof | Balkan Medical Journal | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | [Keyword Not Available] | en_US |
| dc.title | The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Turkiye | en_US |
| dc.type | Article | en_US |












